KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short term Debt (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Short term Debt for 11 consecutive years, with $710.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Short term Debt changed N/A to $710.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $710.7 million, a N/A change, with the full-year FY2022 number at $13.3 million, down 85.09% from a year prior.
  • Short term Debt was $710.7 million for Q3 2025 at Halozyme Therapeutics, up from $9.9 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $710.7 million in Q3 2025 to a low of $9.9 million in Q2 2025.
  • A 3-year average of $129.3 million and a median of $89.2 million in 2021 define the central range for Short term Debt.
  • Peak YoY movement for Short term Debt: skyrocketed 3014.45% in 2021, then tumbled 85.09% in 2022.
  • Halozyme Therapeutics' Short term Debt stood at $89.4 million in 2021, then crashed by 85.09% to $13.3 million in 2022, then surged by 5229.87% to $710.7 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Short term Debt are $710.7 million (Q3 2025), $9.9 million (Q2 2025), and $13.3 million (Q4 2022).